Wheeler Bio Announces Oversubscribed $35M Series, Plans for Expansion and Continued Growth

Wheeler Bio宣布超额认购3500万美元系列融资，计划进行扩张并持续增长

OKLAHOMA CITY, March 20, 2025-- Wheeler Bio, an innovative contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, announced the closing of an oversubscribed Series A-1 financing round. The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises..

俄克拉荷马城，2025年3月20日 —— Wheeler Bio是一家专注于抗体疗法工艺开发和cGMP生产的创新型合同开发与制造组织（CDMO），宣布完成了超额认购的A-1轮融资。这轮3500万美元的融资由Alloy Therapeutics和Echo Investment Capital（Echo）领投，三菱公司（美洲）、Germin8 Ventures和Russell Westbrook Enterprises参与投资。

Wheeler Bio is a high science, high touch CDMO built upon its foundational scientific platform, Modular CMC. Along with supporting the ongoing success of clients, this financing will broaden Wheeler’s capabilities and pave the way for future growth – including planning the build-out of a 52,000 square foot large scale biologics manufacturing facility adjacent to a biomanufacturing workforce training center (BioTC) at Convergence in the Oklahoma City Innovation District..

Wheeler Bio 是一家基于其基础科学平台 Modular CMC 构建的高科学性、高接触型合同开发与生产组织 (CDMO)。在支持客户持续成功的同时，此次融资将拓展 Wheeler 的能力，并为未来发展铺平道路——包括计划在俄克拉荷马城创新区 Convergence 的生物制造劳动力培训中心 (BioTC) 旁建设一座占地 52,000 平方英尺的大规模生物制品生产设施。

“This investment will fuel Wheeler’s ongoing efforts to expand its partner base, team, and capabilities in order to accelerate the advancement of our partners’ therapies,” said Patrick Lucy, President and Chief Executive Officer of Wheeler Bio. “Wheeler’s scientific team and Modular CMC platform coupled with our customer intimate approach is well positioned to enable our partners through clinical and commercial manufacturing.”.

“这项投资将推动Wheeler继续扩大其合作伙伴基础、团队和能力，以加速我们合作伙伴疗法的进展，”Wheeler Bio总裁兼首席执行官Patrick Lucy表示。“Wheeler的科学团队和模块化CMC平台，加上我们以客户为中心的方法，能够很好地帮助我们的合作伙伴实现临床和商业化生产。”

'This investment accelerates Wheeler Bio’s growth and expands its ability to deliver high-quality CMC services for antibody-based therapies,' said Errik Anderson, Founder and CEO of Alloy Therapeutics. 'Alloy has supported Wheeler since its inception, and as the company has honed its overall strategy and advanced its cGMP capabilities under Patrick Lucy’s proven leadership, we are deepening our commitment.

“这项投资加速了Wheeler Bio的增长，并扩大了其为抗体疗法提供高质量CMC服务的能力，”Alloy Therapeutics创始人兼首席执行官Errik Anderson表示。“Alloy自Wheeler成立以来一直支持该公司，随着公司在Patrick Lucy的成熟领导下不断完善整体战略并提升其cGMP能力，我们正在加深我们的承诺。”

Wheeler has a clear path to expanded capabilities and large-scale production, we’re excited to continue supporting its growth and impact on drug development.'.

惠勒有明确的路径来扩展能力和大规模生产，我们很高兴继续支持其增长以及对药物开发的影响。

“Wheeler Bio continues to redefine the art of the possible for drug development in the United States,” said Christian Kanady, Co-Founder of Wheeler Bio and Founding Partner and CEO of Echo. “This impressive line-up of investors symbolizes both deepened and new partnerships that will be significant as Wheeler accelerates growth and ultimately scales its footprint in Oklahoma City and beyond.”.

“Wheeler Bio继续重新定义美国药物开发的可能性，”Wheeler Bio的联合创始人、Echo的创始合伙人兼首席执行官Christian Kanady表示，“这批令人印象深刻的投资者阵容象征着深化和全新的合作伙伴关系，这对于Wheeler加速增长并最终扩大其在俄克拉荷马城及更广泛地区的影响力具有重要意义。”

“Wheeler Bio is perfectly positioned to meet the growing demand for platforms that accelerate the transition from bench to bedside. We are excited for this collaboration so that Wheeler Bio can perform a crucial role in creating an infrastructure to support biotechnology companies that have innovative ideas significantly improving patient quality of life,” said Takahiro Tokuda, Healthcare Division COO, Mitsubishi Corporation..

“Wheeler Bio非常适合满足市场对加速从实验室到临床转化平台日益增长的需求。我们对此次合作感到兴奋，这将使Wheeler Bio在创建支持生物技术公司的基础设施中发挥关键作用，这些公司拥有显著改善患者生活质量的创新理念，”三菱公司医疗保健事业部首席运营官德田隆弘表示。

About Wheeler Bio, Inc.

关于惠勒生物公司

Wheeler Bio is an innovative biopharmaceutical contract development and manufacturing organization (CDMO) founded by a team of industry experts and strategic investors who believe a high science/high touch CDMO model is needed to enable innovators to advance programs more efficiently.

Wheeler Bio 是一家创新的生物制药合同开发和制造组织 (CDMO)，由一群行业专家和战略投资者创立，他们相信需要一种高科学/高接触的 CDMO 模式来帮助创新者更高效地推进项目。

Through its unique scientific platform Modular CMC, Wheeler Bio revolutionizes the speed of drug development by enabling the rapid advancement of antibody-based therapeutic candidates from discovery into human clinical trials while establishing a robust chemistry, manufacturing, and controls (CMC) package vital for regulatory filings and ongoing cGMP manufacturing.

通过其独特的科学平台Modular CMC，Wheeler Bio通过快速将基于抗体的治疗候选药物从发现推进到人体临床试验，彻底改变了药物开发的速度，同时建立了一个对监管申报和持续的cGMP生产至关重要的强大化学、制造和控制（CMC）体系。

This includes a full complement of integrated services including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, technology transfer and cGMP manufacturing..

这包括一整套综合服务，包括可制造性评估、稳定细胞池和克隆开发、工艺和分析方法开发、工艺验证、技术转移以及cGMP生产。

Wheeler Bio is headquartered in Oklahoma City, which has long been a hub of production, distribution, and business services. Key advantages include consistently lower business costs and a growing biomanufacturing workforce. In 2022, the Oklahoma Biotech Innovation Cluster was awarded $35M by the U.S.

惠勒生物公司总部位于俄克拉荷马城，这里长期以来一直是生产、分销和商业服务的中心。其关键优势包括持续较低的商业成本以及不断增长的生物制造劳动力。2022年，俄克拉荷马生物技术创新集群获得了美国政府3500万美元的拨款。

Economic Development Administration to advance the Oklahoma City region’s emerging bioeconomy, including specific funding for biomanufacturing workforce development and bioprocessing core labs..

经济发展管理局推动俄克拉荷马城地区新兴的生物经济，包括为生物制造劳动力发展和生物处理核心实验室提供专项资金。

Join the Wheeler Bio community by visiting wheelerbio.com or following the company on LinkedIn.

通过访问 wheelerbio.com 或在 LinkedIn 上关注该公司，加入 Wheeler Bio 社区。

Contact:

联系人：

For Further Information:

更多信息：

Wheeler Bio, Inc.

惠勒生物公司

Contact: Jaden Polston

联系人：贾登·波尔斯顿

info@wheelerbio.com

info@wheelerbio.com